Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HLA DR15 and immunobiologic outcomes

Minoo Battiwalla, Theresa Hahn, Philip L McCarthy

    Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
    |February 24, 2007
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA).

    Transplantation and cellular therapy·2026
    Same author

    Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

    Blood advances·2026
    Same author

    The suppressive function of ILC2 cells is regulated by β2-adrenergic receptor signaling in breast cancer.

    NPJ breast cancer·2026
    Same author

    TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study.

    Blood advances·2026
    Same author

    Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin's Lymphoma: Insights From A US Multicenter Transplant and Cellular Therapy Network.

    Transplantation and cellular therapy·2026
    Same author

    Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

    Blood·2026